Skip to content
Inciteful Med

Systemic Treatments: Pills, Infusions, and the Pipeline

Last updated:

Systemic treatments for Sjögren’s are prescribed when the disease affects joints or internal organs. Hydroxychloroquine (Plaquenil) is the standard first-line medication to stabilize the immune system. For severe cases, doctors may use immunosuppressants like Methotrexate or biologics like Rituximab.

Key Takeaways

  • • Hydroxychloroquine (Plaquenil) is the first-line systemic treatment to stabilize the immune system but takes 3-6 months to work.
  • • Systemic medications are primarily used for extraglandular symptoms like joint pain and organ inflammation, not just dryness.
  • • Stronger immunosuppressants like Methotrexate are used when the disease affects joints or lungs.
  • • Rituximab is a potent biologic infusion reserved for severe complications like vasculitis.
  • • New drugs like Ianalumab are in the pipeline and show promise for treating both systemic activity and dryness.

When topical treatments like eye drops are no longer enough to manage the full scope of Sjögren’s, your rheumatologist may discuss systemic treatments—medications that work throughout your entire body. These drugs are generally reserved for patients with moderate to severe “extraglandular” involvement, such as joint pain, profound fatigue, or organ inflammation [1][2].

The First Line: Hydroxychloroquine (Plaquenil)

Hydroxychloroquine (HCQ) is the most frequently prescribed systemic drug for Sjögren’s [3]. It is considered a “disease-modifying” drug that helps calm an overactive immune system.

  • What it helps: HCQ is often effective for treating inflammatory joint pain and may reduce the risk of future systemic complications [4][5].
  • Timeline: It is not a quick fix. HCQ works slowly, often taking 3 to 6 months to reach full effect [6]. Patience is key.
  • The Reality Check: While it is a staple of treatment, research on its ability to improve fatigue is mixed, with some studies showing little benefit over a placebo [4][6]. Importantly, HCQ rarely improves objective dryness (tear or saliva flow) in most patients [4].
  • Safety: It is generally safe for long-term use, though it requires regular eye exams to monitor for a rare risk of retinal toxicity [7].

Steroid-Sparing Immunosuppressants

If your disease affects your joints, skin, or internal organs (like the lungs or kidneys), your doctor may use stronger “steroid-sparing” medications to reduce your reliance on Prednisone [8][9].

  • Methotrexate (MTX): Commonly used for inflammatory arthritis associated with Sjögren’s. Some patients find it more effective for fatigue than HCQ alone [10][11].
  • Mycophenolate Mofetil (CellCept) & Azathioprine: Often reserved for more serious organ involvement, such as interstitial lung disease or kidney inflammation [12][13].

Targeted Biologics: Rituximab (Rituxan)

Rituximab is a powerful “B-cell depleting” therapy given by infusion. It is not usually a first-line treatment but is highly effective for specific, severe systemic complications [14].

  • Clinical Indications: It is the preferred treatment for vasculitis (blood vessel inflammation) and cryoglobulinemia (abnormal proteins in the blood) [15][16].
  • Other Uses: It may also be used for severe parotid gland swelling or inflammatory lung disease that hasn’t responded to other drugs [14].

The Role of Steroids (Prednisone)

Corticosteroids like Prednisone are excellent for quickly calming a “flare” or treating sudden organ involvement [9]. However, they are generally used at the lowest dose for the shortest time possible because long-term use is associated with risks like bone loss and an increased risk of heart disease [17].

The Pipeline: Hope for the Future

The most exciting area of Sjögren’s research is the development of new biologics that target the specific biological pathways of the disease.

  • Ianalumab (VAY736): In Phase 2 trials, this drug showed a significant reduction in overall disease activity and even some evidence of improved salivary flow [18][19].
  • Dazodalibep: This drug works by blocking “co-stimulation” signals between immune cells. Recent trials showed it significantly improved both the systemic disease score (ESSDAI) and the patient’s reported symptom burden [20][21].

Summary of Systemic Options

Medication Typical Use Main Benefit
Hydroxychloroquine First-line systemic Joint pain, overall disease stability [5].
Methotrexate Arthritis / Skin issues Reducing joint inflammation [10].
Rituximab Severe systemic / Vasculitis Treating B-cell related complications [15].
Prednisone Acute flares Rapid relief of severe inflammation [9].
Ianalumab* Clinical Trials Potential for systemic and dryness relief [18].
*Currently in clinical trials, not yet FDA-approved for Sjögren’s.

Frequently Asked Questions

When is systemic treatment necessary for Sjögren’s?
Systemic treatments are generally reserved for patients with moderate to severe "extraglandular" involvement. This includes symptoms beyond dryness, such as significant joint pain, profound fatigue, or inflammation in organs like the lungs or kidneys.
How long does Hydroxychloroquine (Plaquenil) take to work?
Hydroxychloroquine acts slowly in the body. It typically takes 3 to 6 months of consistent use to reach its full effect, so patience is required when starting this medication.
Does Hydroxychloroquine help with dry eyes and dry mouth?
While Hydroxychloroquine is effective for joint pain and disease stability, research shows it rarely improves objective dryness (tear or saliva flow). Its ability to improve fatigue is also mixed, with some studies showing limited benefit.
What is Rituximab used for in Sjögren’s patients?
Rituximab is a powerful B-cell depleting therapy usually reserved for severe complications. It is the preferred treatment for vasculitis (blood vessel inflammation) and cryoglobulinemia, or for lung disease that hasn't responded to other drugs.
Are there new drugs being developed for Sjögren’s?
Yes, new biologics like Ianalumab and Dazodalibep are currently in clinical trials. These drugs target specific biological pathways and have shown promise in reducing disease activity and potentially improving salivary flow.

Questions for Your Doctor

  • • Based on my ESSDAI score (systemic disease activity), am I a candidate for systemic treatment rather than just symptom management?
  • • Is Hydroxychloroquine likely to help my specific level of fatigue, or should we consider other options like Methotrexate?
  • • Given my lab results (such as cryoglobulins or low complement), would I benefit from a B-cell depleting therapy like Rituximab?
  • • How long should I remain on Prednisone during this flare, and what is our plan to transition to a steroid-sparing medication?
  • • Are there any clinical trials for Ianalumab or Dazodalibep currently enrolling at this facility?

Questions for You

  • • Have you noticed any new systemic symptoms like purple skin spots (purpura), shortness of breath, or new joint swelling?
  • • How would you describe your fatigue: is it improved by rest, or does it feel like a constant 'biological' exhaustion?
  • • Are you willing to consider medications with more complex monitoring (like regular bloodwork or infusions) to address your systemic symptoms?
  • • Have you had an eye exam in the last year to establish a baseline for your retinal health before starting Hydroxychloroquine?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Current and future treatment in primary Sjögren's syndrome - A still challenging development.

    Ritter J, Chen Y, Stefanski AL, Dörner T

    Joint bone spine 2022; (89(6)):105406 doi:10.1016/j.jbspin.2022.105406.

    PMID: 35537697
  2. 2

    Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.

    Iwata N, Tomiita M, Kobayashi I, et al.

    Pediatric rheumatology online journal 2020; (18(1)):73 doi:10.1186/s12969-020-00458-1.

    PMID: 32943063
  3. 3

    An Early View of Iran Primary Sjogren Syndrome Registry (Guilan Province Pilot Phase), an Emerging Effort for a National Registry Establishment.

    Hajiabbasi A, Jamshidi A, Monfared A, et al.

    Medical journal of the Islamic Republic of Iran 2024; (38()):134 doi:10.47176/mjiri.38.134.

    PMID: 39968468
  4. 4

    Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.

    Wang SQ, Zhang LW, Wei P, Hua H

    BMC musculoskeletal disorders 2017; (18(1)):186 doi:10.1186/s12891-017-1543-z.

    PMID: 28499370
  5. 5

    Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.

    Demarchi J, Papasidero S, Medina MA, et al.

    Clinical rheumatology 2017; (36(11)):2455-2460 doi:10.1007/s10067-017-3822-3.

    PMID: 28913747
  6. 6

    The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.

    Wang X, Zhang T, Guo Z, et al.

    Frontiers in pharmacology 2021; (12()):693796 doi:10.3389/fphar.2021.693796.

    PMID: 34588979
  7. 7

    Hydroxychloroquine retinopathy.

    Yusuf IH, Sharma S, Luqmani R, Downes SM

    Eye (London, England) 2017; (31(6)):828-845 doi:10.1038/eye.2016.298.

    PMID: 28282061
  8. 8

    Kidney manifestations of pediatric Sjögren's syndrome.

    La Bella S, Vivarelli M, Di Ludovico A, et al.

    Pediatric nephrology (Berlin, Germany) 2024; (39(3)):711-721 doi:10.1007/s00467-023-06135-1.

    PMID: 37638982
  9. 9

    Childhood-onset primary Sjögren's Syndrome presenting as nephrotic syndrome: a case report and literature review.

    Song Y, Sun L, Cui G, et al.

    BMC pediatrics 2025; (25(1)):721 doi:10.1186/s12887-025-06029-1.

    PMID: 41039282
  10. 10

    Livedoid Vasculitis in a Patient With Sjogren Syndrome Successfully Treated With Methotrexate.

    Aldehaim AY, Alarfaj AS

    Clinical medicine insights. Case reports 2022; (15()):11795476221088489 doi:10.1177/11795476221088489.

    PMID: 35342318
  11. 11

    Improved Fatigue Management in Primary Sjögren's Syndrome: A Retrospective Analysis of the Efficacy of Methotrexate in Chinese Patients.

    Zhou M, Dai X, Yuan F

    Journal of inflammation research 2024; (17()):7551-7560 doi:10.2147/JIR.S475605.

    PMID: 39464343
  12. 12

    Sjögren's Syndrome Associated with Fanconi's Syndrome and Osteomalacia.

    Gutierrez JO, Zurita MF, Zurita LA

    The American journal of case reports 2018; (19()):392-396 doi:10.12659/ajcr.907503.

    PMID: 29610453
  13. 13

    Pulmonary manifestations of Sjögren's syndrome.

    Flament T, Bigot A, Chaigne B, et al.

    European respiratory review : an official journal of the European Respiratory Society 2016; (25(140)):110-23 doi:10.1183/16000617.0011-2016.

    PMID: 27246587
  14. 14

    Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.

    Carsons SE, Vivino FB, Parke A, et al.

    Arthritis care & research 2017; (69(4)):517-527 doi:10.1002/acr.22968.

    PMID: 27390247
  15. 15

    The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.

    Roccatello D, Sciascia S, Rossi D, et al.

    Oncotarget 2017; (8(25)):41764-41777 doi:10.18632/oncotarget.16986.

    PMID: 28454112
  16. 16

    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.

    Emmanuel B, Sidique N, Zhang X, et al.

    Journal of viral hepatitis 2017; (24(2)):128-131 doi:10.1111/jvh.12618.

    PMID: 27666584
  17. 17

    Increased risk of coronary heart disease among patients with primary Sjögren's syndrome: a nationwide population-based cohort study.

    Wu XF, Huang JY, Chiou JY, et al.

    Scientific reports 2018; (8(1)):2209 doi:10.1038/s41598-018-19580-y.

    PMID: 29396489
  18. 18

    Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.

    Dörner T, Posch MG, Li Y, et al.

    Annals of the rheumatic diseases 2019; (78(5)):641-647 doi:10.1136/annrheumdis-2018-214720.

    PMID: 30826774
  19. 19

    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.

    Bowman SJ, Fox R, Dörner T, et al.

    Lancet (London, England) 2022; (399(10320)):161-171 doi:10.1016/S0140-6736(21)02251-0.

    PMID: 34861168
  20. 20

    CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.

    St Clair EW, Baer AN, Ng WF, et al.

    Nature medicine 2024; (30(6)):1583-1592 doi:10.1038/s41591-024-03009-3.

    PMID: 38839899
  21. 21

    [Focus on Sjögren's syndrome - Diagnosis and treatment].

    Zehrfeld N, Witte T, Ernst D

    Deutsche medizinische Wochenschrift (1946) 2024; (149(12)):734-739 doi:10.1055/a-2136-3498.

    PMID: 38781999

This guide outlines systemic medications for Sjögren’s for educational purposes. Medication decisions and risk assessments should always be made in consultation with your rheumatologist.

Stay up to date

Get notified when new research about Sjögren's Syndrome is published.

No spam. Unsubscribe anytime.